Oncotarget and the E-Cigarette Study

Electronic cigarettes have been found to be just as damaging to teeth and gums as the “traditional” cigarette, according to a recent study by the Rochester Medical center.

The study was led by Irfan Rahman, Ph.D. and was published in Oncotarget. It is the very first study to be conducted in order to address the effects of e-cigarettes on oral health at cellular and molecular levels.

Electronic cigarettes have grown in popularity with former smokers as well as young adults mostly n part to the perception that they are better for your health than the “old school” cigarettes. Scientists once thought that the chemicals found in smoke form cigarettes were the enemy as far as adverse health effects but recent research has proven the opposite. Follow Oncotarget on Twitter.

When vapors are burned from an e-cigarette, it releases inflammatory proteins form cells which results in damage that can potentially lead to many different oral diseases. How often and how much a person uses an e-cigarette will determine the amount of damage the oral cavity and gums will be subjected to. Flavorings have been found to cause even more damage to cells-some more than others. E-cigarettes contain nicotine and nicotine contributes to gum disease.

Most electronic cigarettes contain a heating device, a battery, and a cartridge that holds liquid. The cartridge holds the flavorings, nicotine, and other potentially damaging chemicals. When the device heats up, it changes the liquid in the cartridge into an aerosol that the user can then inhale. There is still a lot more research that needs to be done in order to better understand the effects of using an e-cigarette, according to Rahman.

Visit: https://www.facebook.com/Oncotarget/

Oncotarget is a journal that focuses on the pathological basis of cancers, targets for therapy and treatment of cancers in patients. The international journal focuses heavily on the impact of management programs and therapeutic protocols and agents on patients to get a better perspective. Oncotarget is finding new evidence behind new and existing therapies in order to improve possible outcomes and seeks to define their usage by the patient as well as the health care professional.